These Biotechs Were Focused on One Line on Pfizer’s Earnings Report

The $79 million that Vyndaqel contributed to Pfizer's (NYSE: PFE) third-quarter revenue doesn't mean a whole lot to the pharmaceutical giant. It amounted to a whopping 0.6% of the company's overall revenue.

But you can bet that executives at Alnylam Pharmaceuticals (NASDAQ: ALNY), Akcea Therapeutics (NASDAQ: AKCA), Ionis Pharmaceuticals (NASDAQ: IONS), and Eidos Therapeutics (NASDAQ: EIDX) were checking sales of the drug after its first full quarter on the market in the U.S.